According to related industries, Galderma Korea's AKLIEF passed the Drug Committee (DC) of higher general hospitals such as Samsung Medical Center and Sinchon Severance Hospital.

AKLIEF is a retinoid-based treatment that has been recommended as the primary treatment for acne, and is evaluated as an innovative treatment that can simultaneously treat face and torso acne by overcoming the limitations of existing treatments that have been limited to face acne treatment.

Acne is known to occur mainly on the face, but body acne is a common phenomenon. 50% of patients with acne on their faces develop body acne together. According to a clinical study of 965 people, chest and torso acne rates were